Huntington's disease

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament…

<!-- Name:DistributionId Value:8793201 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases including Alzheimer’s ROCHESTER, N.Y., Aug.…

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12…

New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and structure of the central nervous system or…

Salt Lake City, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site operations. CenExel Rocky Mountain…

~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ ~ Full Study Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug. 30, 2021 (GLOBE NEWSWIRE) --…